JAMES EYERMAN: Open Payments
NPI 1588615843 · SAN FRANCISCO, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$13,244 in 23 payments from 6 companies in 2025. Trend: 2023 $1,341 · 2024 $13,807 · 2025 $13,244
Speaker / faculty: $12,177Food & beverage: $966Education: $101
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 8 | $12,513 |
| E.R. Squibb & Sons, L.L.C. | 7 | $213 |
| Neurocrine BioSciences, Inc. | 2 | $165 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $151 |
| Alkermes, Inc. | 1 | $128 |
| Janssen Pharmaceuticals, Inc | 2 | $73 |
Products named: UZEDY, COBENFY, INGREZZA, CAPLYTA, LYBALVI, INVEGA SUSTENNA.
Industry payments across CA — which companies pay providers there.
